EU Approval Recommendations: Strong Showing From Orphans & Biosimilars
Executive Summary
The CHMP has recommended 11 products for approval at its latest meeting, including four orphan medicines, three biosimilars and two generics. It also recommended harmonizing the product labeling for two etoposide products.
You may also be interested in...
Univar’s Cufence Approved In EU For Wilson’s Disease, But Loses Orphan Status
Cufence, which has just been authorized for EU-wide marketing, is one of two trientine products for Wilson’s disease to lose their orphan designation.
All Set For EU Approval: First Biosimilar Humalog And Three More Rituximabs From Celltrion
The European Medicines Agency has given the thumbs-up to Insulin lispro Sanofi, the first biosimilar version of Lilly’s diabetes drug Humalog. It has also green-lighted three more biosimilar rituximab products from Celltrion, which already has EU approval for one version of the originator product, Roche’s MabThera.
All Set For EU Approval: First Biosimilar Humalog And Three More Rituximabs From Celltrion
The European Medicines Agency has given the thumbs-up to Insulin lispro Sanofi, the first biosimilar version of Lilly’s diabetes drug Humalog. It has also green-lighted three more biosimilar rituximab products from Celltrion, which already has EU approval for one version of the originator product, Roche’s MabThera.